Compare · ABT vs KRRO
ABT vs KRRO
Side-by-side comparison of Abbott Laboratories (ABT) and Korro Bio Inc. (KRRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and KRRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 1321.2x KRRO ($137.1M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 3 for KRRO).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Korro Bio Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $137.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest KRRO
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 8-K filed by Korro Bio Inc.
- Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
- Director Formela Jean Francois sold $686,177 worth of shares (48,690 units at $14.09) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver sold $69 worth of shares (5 units at $13.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.03% to 16,241 units (SEC Form 4)
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Senior Vice President, Finance Dolan Oliver sold $99,368 worth of shares (7,353 units at $13.51) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 16,246 units (SEC Form 4)
- Director Formela Jean Francois sold $4,188 worth of shares (300 units at $13.96) as part of a pre-agreed trading plan (SEC Form 4)
- Korro to Participate in Upcoming Investor Conferences
- Director Formela Jean Francois sold $398,552 worth of shares (28,468 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)